List of Excipients in Branded Drug AMETHYST

Generic Drugs Containing AMETHYST

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	levonorgestrel and ethinyl estradiol	0480-3472	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	levonorgestrel and ethinyl estradiol	0480-3472	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals Inc	levonorgestrel and ethinyl estradiol	0480-3472	LACTOSE MONOHYDRATE
Teva Pharmaceuticals Inc	levonorgestrel and ethinyl estradiol	0480-3472	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in AMETHYST?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE

Amethyst Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Amethyst is the former brand name for a continuous oral contraceptive containing levonorgestrel 90 mcg and ethinyl estradiol 20 mcg per tablet. Its commercial value now lies primarily in generic substitution, low-dose formulation optimization, differentiated packaging, and lifecycle products rather than in the original brand. The core excipient strategy should prioritize dose uniformity, hormone stability, tablet robustness, dissolution control, and low-cost high-volume manufacturing.

What drug is Amethyst and how is it formulated?

Amethyst was a 28-day, extended-cycle combined oral contraceptive. Unlike conventional 21/7 regimens, all 28 tablets contained active hormonal ingredients, allowing continuous administration and reducing scheduled withdrawal bleeding.

Product attribute	Amethyst
Active ingredients	Levonorgestrel 90 mcg; ethinyl estradiol 20 mcg
Dosage form	Immediate-release oral tablet
Administration	One tablet daily without a hormone-free interval
Therapeutic class	Combined hormonal contraceptive
Original regulatory pathway	FDA-approved NDA product
Current opportunity	Generic oral contraceptive and lifecycle reformulation
Primary technical challenge	Uniform distribution of microgram quantities of potent hormones

The labeled inactive ingredients for Amethyst-type levonorgestrel/ethinyl estradiol tablets include lactose monohydrate, microcrystalline cellulose, polacrilin potassium, and magnesium stearate. Product-specific formulations may differ by manufacturer, particularly in coating systems, colorants, processing aids, and tablet-strengthening excipients. The FDA-approved labeling identifies the dosage form, active ingredients, warnings, and inactive ingredients for the marketed product. [1]

What excipients protect the performance of Amethyst tablets?

The most important excipient functions are content uniformity, powder flow, compressibility, disintegration, lubrication, and chemical stability.

Lactose monohydrate

Lactose provides bulk for a tablet containing only microgram quantities of hormones. It also supports direct compression or low-shear granulation, depending on particle size and grade.

Commercial advantages include low cost, broad regulatory familiarity, and availability from multiple suppliers. The principal limitations are lactose intolerance concerns, supplier variability in particle-size distribution, and potential interaction risks in poorly controlled moisture environments.

A generic developer can differentiate by using a spray-dried lactose grade to improve flow and compactibility. Anhydrous lactose may be considered where moisture control is critical, although the change requires comparative formulation and stability work.

Microcrystalline cellulose

Microcrystalline cellulose contributes compactibility, tablet hardness, and structural integrity. It can reduce capping and friability when the hormone premix is diluted into a larger carrier system.

MCC grade selection affects tablet weight, disintegration, and compression force. A high-density grade may improve die filling and throughput. A lower-density grade may improve disintegration but increase powder volume and segregation risk.

Polacrilin potassium

Polacrilin potassium functions as a superdisintegrant and ion-exchange resin. It can promote rapid tablet breakup at relatively low use levels. For a low-dose hormonal tablet, this supports consistent dissolution without requiring a large disintegrant load.

The main development issue is balance. Excessive disintegrant may reduce tablet strength or alter blend behavior. The excipient can also influence moisture uptake and should be evaluated under accelerated stability conditions.

Magnesium stearate

Magnesium stearate is the principal lubricant in the conventional formulation strategy. It reduces ejection force and prevents sticking during compression.

Over-lubrication can produce a hydrophobic tablet surface, slow disintegration, and reduce dissolution. Blend time, lubricant concentration, specific surface area, and shear exposure should be controlled as critical process parameters.

Film coating and colorants

Film coating can improve swallowability, handling, identification, and moisture protection. A simple aqueous hypromellose-based coating is generally preferable for a low-cost generic unless the formulation has a demonstrated light or moisture sensitivity.

Color coding can support product identification and medication adherence. The commercial value is limited unless the product is sold through a differentiated consumer or specialty channel. Colorants also increase formulation complexity and may create supply, allergen, or market-access issues.

What is the best excipient strategy for a generic Amethyst product?

A practical generic strategy is a low-weight immediate-release tablet based on a validated hormone premix, lactose or MCC dilution, a superdisintegrant, and controlled magnesium stearate lubrication.

Recommended formulation architecture

Formulation element	Strategic role	Development priority
Levonorgestrel and ethinyl estradiol premix	Dose uniformity	Highest
Lactose or spray-dried lactose	Diluent and flow aid	High
Microcrystalline cellulose	Compression and hardness	High
Polacrilin potassium or equivalent disintegrant	Rapid breakup	High
Magnesium stearate	Ejection and anti-sticking	Medium
Hypromellose film coat	Identification and handling	Medium
Moisture barrier packaging	Stability protection	High

The key manufacturing control is premixing. Hormone quantities are too small to distribute reliably by simple direct blending without a validated dilution sequence. A geometric dilution process, ordered addition of carrier excipients, and blend-uniformity sampling are central to commercial scale-up.

Low-dose hormones also create occupational exposure concerns. Closed transfer, contained dispensing, dedicated equipment or validated cleaning, and appropriate industrial hygiene controls are required. These controls can become a meaningful manufacturing barrier even when the composition itself is simple.

Which excipient choices create intellectual-property opportunities?

Excipient patents are unlikely to protect the basic Amethyst composition after expiration of the original product and formulation rights. Commercially relevant protection would more likely arise from specific formulation or process claims.

Potential formulation claim areas

A developer could pursue claims directed to:

• A defined particle-size distribution for hormone-containing granules.
• A specific premix ratio that improves content uniformity.
• A low-moisture tablet system that improves hormone stability.
• A controlled disintegration profile for continuous-dose contraception.
• A coating that limits light or moisture degradation.
• A formulation that reduces tablet weight while maintaining hardness.
• A composition that avoids a particular excipient associated with intolerance or supply risk.
• A packaging and formulation combination that extends shelf life.

Patent strength would depend on comparative data. A claim covering common excipients at routine concentrations would face obviousness risk. Stronger protection would require an unexpected result, such as materially improved stability, dissolution, content uniformity, or manufacturing yield.

Process and manufacturing claims

Process protection may be more commercially useful than composition protection. Potential claim subjects include:

• Sequential dilution of microgram-dose hormones.
• Low-shear blending that limits segregation.
• Roller compaction or dry granulation parameters.
• In-process sampling methods for blend uniformity.
• Contained manufacturing systems for potent hormonal APIs.
• Cleaning validation methods for estrogen and progestin residues.

Process patents can be difficult to enforce unless the manufacturing steps are discoverable or reflected in regulatory filings. Trade-secret protection may be more practical for blend order, equipment settings, and scale-up parameters.

What FDA regulatory issues affect Amethyst excipient commercialization?

A generic version would generally proceed through an abbreviated new drug application, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. The formulation does not need to use the same excipients as the reference product unless an excipient difference creates a safety, performance, or regulatory issue.

The developer must demonstrate that excipient changes do not adversely affect:

• Assay and content uniformity.
• Dissolution across relevant media.
• Degradation products.
• Tablet robustness.
• Stability through the proposed shelf life.
• Bioequivalence.
• Labeling and inactive-ingredient acceptability.

For oral products, the FDA Inactive Ingredient Database can support precedent for excipient use, but precedent does not eliminate the need for product-specific quality and performance data. FDA guidance on ANDAs, bioequivalence, pharmaceutical development, and process validation remains relevant. [2-4]

The estrogen component creates additional manufacturing and containment scrutiny. The quality system should address cross-contamination, cleaning verification, operator exposure, and environmental controls.

When did Amethyst lose exclusivity and what is the generic entry outlook?

The original Amethyst product was approved in 2007. The brand is no longer the principal commercial driver, and generic levonorgestrel/ethinyl estradiol 90 mcg/20 mcg tablets have been marketed. The relevant business question is therefore not a future first generic launch but whether a new entrant can achieve acceptable economics in an established, price-sensitive market.

Commercial factor	Impact on entry
Low active-ingredient cost	Supports manufacturing economics
Microgram-dose uniformity	Raises development and quality risk
Established generic competition	Compresses price
Continuous-use regimen	Provides clinical differentiation
Large contraceptive market	Supports volume
Hormonal containment requirements	Raises capital and operating costs
Limited formulation complexity	Reduces technical barrier
Brand discontinuation	Limits premium pricing

The principal entry risks are rapid price erosion, payer substitution, limited shelf space, and the cost of maintaining reliable supply. A new generic would need either a lower cost base, a reliable shortage-prevention profile, a differentiated channel strategy, or a meaningful product improvement.

What commercial opportunities exist for Amethyst-type products?

Low-cost generic supply

The most direct opportunity is a dependable, low-cost generic product. Contract manufacturing can reduce capital requirements, but the sponsor must verify that the contractor has experience with low-dose hormones and adequate containment controls.

Extended-cycle contraceptive portfolio

Amethyst-type tablets can anchor a broader portfolio that includes:

• Conventional 21/7 combined oral contraceptives.
• Extended-cycle regimens.
• Progestin-only tablets.
• Emergency contraception.
• Transdermal or vaginal delivery systems.
• Patient-specific packaging for adherence support.

The value of a portfolio approach is manufacturing leverage and broader formulary access. The same commercial infrastructure can support several hormonal products.

Differentiated packaging

Packaging is a practical area for product differentiation. Options include calendar blister packs, adherence-oriented labeling, multilingual instructions, and packaging designed to minimize missed doses.

Packaging patents are possible but often weak unless the design has a specific technical function. Trademark, trade dress, and channel execution may produce greater commercial value.

Excipient-reduced or lactose-free formulation

A lactose-free product could address prescriber and patient preferences, although the clinical need is limited because the lactose quantity in a tablet is generally small. The opportunity is strongest where a manufacturer can maintain equivalent dissolution and tablet robustness without raising cost.

Potential replacement systems include combinations of MCC, mannitol, dibasic calcium phosphate, crospovidone, or other established diluents and disintegrants. Each change requires evaluation of hardness, friability, blend segregation, dissolution, and stability.

Stability-enhanced product

A formulation with improved resistance to humidity, heat, or light could support longer shelf life and reduce distribution losses. The commercial value is greatest in hot and humid markets or supply chains with limited environmental control.

The product may require a higher-barrier blister, desiccant packaging, or a moisture-resistant coating. Packaging changes can be commercially effective even when the tablet composition remains conventional.

Contract development and manufacturing

Specialized manufacturers can generate revenue by offering:

• Hormone premix preparation.
• Low-dose tablet development.
• Contained compression and coating.
• Cleaning-validation packages.
• Stability and dissolution method development.
• Regulatory documentation for generic filings.

The technical barrier is higher than the active ingredient cost suggests because manufacturing failures can result in content-uniformity deviations, cross-contamination events, or regulatory observations.

How does Amethyst compare with competing contraceptive products?

Product category	Main differentiation	Excipient opportunity	Commercial pressure
Conventional combined oral contraceptive	Monthly withdrawal bleeding	Low-cost robust tablet	High generic competition
Amethyst-type continuous regimen	Reduced or eliminated scheduled bleeding	Stability and adherence packaging	Moderate clinical differentiation
Progestin-only pill	Estrogen-free option	Rapid disintegration and dose control	Expanding demand
Long-acting reversible contraception	Multi-year duration	Device and polymer technology	Higher technical barrier
Transdermal or vaginal products	Non-oral delivery	Adhesives, polymers, permeation systems	Greater formulation complexity

Amethyst-type products remain easier to manufacture than long-acting devices, but they have less defensible intellectual property. Their strongest advantages are low development cost, familiar regulatory pathways, and established patient demand for continuous regimens.

What is the patent strength of an Amethyst-type product?

The base tablet has limited prospective patent strength. A conventional combination of levonorgestrel, ethinyl estradiol, lactose, MCC, a disintegrant, and magnesium stearate is vulnerable to prior-art and obviousness challenges.

A stronger estate would require several coordinated layers:

1. Composition claims covering a non-obvious excipient system.
2. Process claims covering hormone premixing and segregation control.
3. Stability claims supported by comparative data.
4. Packaging claims linked to measurable shelf-life improvement.
5. Method-of-use claims covering a distinct continuous-dosing regimen.
6. Trade-secret controls over scale-up and containment processes.

The commercial strategy should not rely on a single formulation patent. Regulatory exclusivity, trademark rights, supply reliability, manufacturing know-how, and payer contracting are more relevant to current market value.

Key Takeaways

• Amethyst is a continuous oral contraceptive containing levonorgestrel 90 mcg and ethinyl estradiol 20 mcg.
• The core excipient platform uses a diluent, MCC, a superdisintegrant, and magnesium stearate.
• The main technical risk is uniform distribution of microgram quantities of potent hormones.
• A new entrant faces generic price pressure and established competition.
• The strongest commercial opportunities are reliable generic supply, stability-enhanced packaging, lactose-free reformulation, adherence packaging, and contract manufacturing.
• Formulation patents require comparative technical data. Routine excipient substitutions are unlikely to provide strong protection.
• Process controls, containment, cleaning validation, and blend uniformity are more important than the nominal simplicity of the tablet.

FAQs

Can Amethyst be reformulated as a chewable or orally disintegrating tablet?

Yes, but the change would create new taste-masking, dose-uniformity, stability, and bioequivalence requirements. The commercial case would depend on adherence benefits and the ability to preserve a low tablet weight.

Are excipient patents available for levonorgestrel and ethinyl estradiol tablets?

Yes. Patents can cover specific excipient combinations, particle sizes, manufacturing methods, coatings, or packaging systems. Broad claims to conventional excipients are likely to face validity challenges.

Is a lactose-free Amethyst generic commercially attractive?

It can be attractive as a differentiated product, but the market premium is uncertain. The formulation must maintain equivalent dissolution, hardness, stability, and manufacturing yield without materially increasing cost.

What packaging provides the best stability strategy for Amethyst-type tablets?

High-barrier blister packaging is generally the leading option where moisture and oxygen control are important. The final choice depends on stability data, distribution conditions, tooling cost, and market requirements.

Can an Amethyst-type product support a 505(b)(2) strategy?

A conventional generic composition normally fits the ANDA pathway more naturally. A 505(b)(2) strategy would require a meaningful change, such as a new dosage form, delivery system, dosing regimen, or other modification supported by new clinical or pharmacokinetic data.

References

1. U.S. Food and Drug Administration. (2007). Amethyst prescribing information: Levonorgestrel and ethinyl estradiol tablets.
2. U.S. Food and Drug Administration. (2023). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
4. U.S. Food and Drug Administration. (2011). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin.